| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0002-8703(99)70460-6 |
| P698 | PubMed publication ID | 9878937 |
| P50 | author | Yunsheng Ma | Q47257728 |
| P2093 | author name string | R C Becker | |
| F Spencer | |||
| J Hebert | |||
| S P Ball | |||
| P Eisenberg | |||
| T Hurley | |||
| S Borzak | |||
| A C Held | |||
| R Jesse | |||
| S J Voyce | |||
| R Hendel | |||
| P2860 | cites work | Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial | Q33611581 |
| Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia II | Q40972097 | ||
| Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association | Q41222678 | ||
| Management of venous thromboembolism | Q41243481 | ||
| A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time | Q42236842 | ||
| Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis | Q43786633 | ||
| Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). | Q44086439 | ||
| The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial | Q47385884 | ||
| Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. | Q51037355 | ||
| Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: Results of GUSTO-I | Q56945210 | ||
| Erroneous activated partial thromboplastin time | Q67349636 | ||
| Variation among commercial activated partial thromboplastin time reagents in response to heparin | Q67569212 | ||
| A Standard Heparin Nomogram for the Management of Heparin Therapy | Q67856239 | ||
| Measurement of the activated partial thromboplastin time from a capillary (fingerstick) sample of whole blood. A new method for monitoring heparin therapy | Q68192230 | ||
| A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators | Q68364308 | ||
| Role of heparin after intravenous thrombolytic therapy for acute myocardial infarction | Q69740665 | ||
| Heparin | Q70147507 | ||
| Assessment of Anticoagulant Treatment of Venous Thromboembolism | Q71219263 | ||
| Heparin and the activated partial thromboplastin time--a difference between the in-vitro and in-vivo effects and implications for the therapeutic range | Q71424202 | ||
| Heparin therapy for deep venous thrombosis | Q71462731 | ||
| Heparin kinetics: variables related to disposition and dosage | Q71509204 | ||
| ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) | Q71724580 | ||
| Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety | Q71732646 | ||
| Bedside coagulation monitoring in heparin-treated patients with active thromboembolic disease: a coronary care unit experience | Q72759632 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heparin | Q190016 |
| thromboembolism | Q891391 | ||
| hospitalization | Q3140971 | ||
| multicenter clinical trial | Q6934595 | ||
| P304 | page(s) | 59-71 | |
| P577 | publication date | 1999-01-01 | |
| P1433 | published in | American Heart Journal | Q2227156 |
| P1476 | title | A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Antithrombotic Therapy Consortium Investigators | |
| P478 | volume | 137 |
| Q22241913 | Q22241913 |
| Q59356505 | ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the M |
| Q43968749 | An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A. |
| Q47204783 | Assessment of weight-based versus standard dosing of heparin in patients with unstable angina |
| Q37792099 | Bleeding complications of unfractionated heparin |
| Q33781183 | Diagnosis and management of patients with unstable angina |
| Q39215277 | Evaluation of 2 weight-based protocols for administration of heparin |
| Q24632951 | Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q82865291 | Heparin dosing and therapeutic activated partial thromboplastin times (aPTT) in acute coronary syndrome (ACS) |
| Q79553992 | Heparin resistance in acute coronary syndromes |
| Q73906883 | Heparins in management of acute coronary syndromes without ST-segment elevation |
| Q28192889 | Low molecular weight heparin and unfractionated heparin in the early pharmacologic management of acute coronary syndromes: a meta-analysis of randomized clinical trials |
| Q34027403 | Low molecular weight heparins and coronary artery disease |
| Q47246171 | Low-molecular-weight heparin as optimal solution to therapeutic heparinization |
| Q33704601 | Low-molecular-weight heparin should replace unfractionated heparin in the management of acute coronary syndromes |
| Q28184399 | New heparin dosing recommendations for patients with acute coronary syndromes |
| Q31857934 | Recommendations and opinions for the use of point-of-care testing for hospitals and primary care: summary of a 1999 symposium |
| Q90070321 | Systematic review of interventions to improve safety and quality of anticoagulant prescribing for therapeutic indications for hospital inpatients |
| Q36583582 | The ineffectiveness of a non-weight based heparin regimen in achieving therapeutic activated partial thromboplastin time (aPTT) in acute coronary syndrome. |
| Q33869572 | The role of point-of-care anticoagulation monitoring in arterial and venous thromboembolic disorders |
| Q73081804 | Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential |
| Q35595796 | Treatment and management of acute venous thromboembolic disease |
| Q26829973 | 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Associat |
Search more.